Sorry to have been so slow to pick up on this one. It's impossible to guess which antidiabetic drug might be best paired with ABL from the data provided by BOM. There's so much about the post hoc subgroup analyses that we do not know - for example, how the other coronary risk factors compared in the different groups. There is enough science there to get the SGLT2 companies very interested, but not to favour one or the other. Perhaps that's the best situation for RVX.

On a different subject, I have a question. We're all waiting for the AGM in the hope/expectation that a BP deal will be announced. But if Don already had a deal, why would he wait until then? Why not come out with it now? Any ideas....?